Kwangdong Pharmaceutical announced on the 8th that it had obtained a patent from the Korean Intellectual Property Office for a method to prevent reduction of the content of ‘L-muscon’, a key ingredient in Solpyo Woo Hwangcheongsimwon.
L-Muscon is a substance that can replace musk in the prescription of Woohwang Cheongsimwon. Musk is considered one of the precious medicinals used in expensive medicines in oriental medicine. However, trade is restricted according to the International Convention on International Trade in Endangered Species of Wild Fauna and Plant Species (CITES), and prices are on the rise.
Pharmaceutical companies have developed and used substances to replace the efficacy of musk. L-muscon was also developed as a substitute for musk and has been included in Woohwang Cheongsimwon, but there was a concern that the content would be reduced during long-term storage due to its strong volatility.
Kwangdong Pharmaceutical has developed a technology that can minimize the volatilization of L-muscon by improving the sealing method of Solpyowoo Hwangcheongsimwon containers. The company explains that the stability of L-muscon contained in Solpyo Woo Hwangcheongsimwon can be further improved through this technology.
Kwangdong Pharmaceutical has been renewing Solpyo-related products, including Solpyo Woo Hwangcheongsimwon, ‘Solpyo Wicheongsu’ and ‘Solpyo Ssang Gamtang’, since it acquired the trademark right for ‘Solpyo’ from Chosun Pharma in July 2017.
An official from Kwangdong Pharmaceutical said, “After acquiring the Solpyo trademark, related products have been continuously released and are receiving good responses such as recalling consumers’ memories.
